The DNA-based nanotransporter developed by Alexis Vallée-Bélisle and his team can transport and deliver precise concentrations of drugs: in this picture, doxorubicin, a chemotherapeutic drug. These nanotransporters can also be attached to specific biomolecules to optimize drug distribution. Here, we see a nanotransporter attached to albumin to maintain doxorubin in blood circulation.
Observing that only about 50 percent of cancer patients get an optimal drug dosage during certain chemotherapy, UdeM Chemistry associate professor Alexis Vallée-Bélisle, an expert in bio-inspired nanotechnologies, started to explore how biological systems control and maintain the concentration of biomolecules.
UdeM PhD student Arnaud Desrosiers, the first author of the study, initially identified and developed two DNA transporters: one for quinine, an antimalarial, and the other for doxorubicin, a commonly used drug for treating breast cancer and leukemia. “Another impressive feature of these nanotransporters,” he added, “is that they can be directed to specific parts of the body where the drug is most needed – and that, in principle, should reduce most side effects.
And, he added, “additionally, these transporters could also be combined with human-designed liposomic transporters that are now being employed to deliver drugs at various rates.”The researchers are now eager to validate the clinical efficiency of their discovery. Since
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: physorg_com - 🏆 388. / 55 Read more »